Stacey E. P. Joosten
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Stacey E. P. Joosten has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Elaine T. Alarid
McArdle Laboratory for Cancer Research, Department of Oncology, Carbone Comprehensive Cancer Center, University of Wisconsin-Madison, Madison, WI 53705, USA
13 shared publications - Geoffrey L. Greene
Ben May Department for Cancer Research, University of Chicago, Chicago, USA
13 shared publications - Hugo Mark Horlings
Department of Pathology The Netherlands Cancer Institute Amsterdam The Netherlands
13 shared publications Irida Kastrati
13 shared publicationsJoshua D. Stender
13 shared publicationsLuis H. Alejo
13 shared publications
Latest Publications
- Open Access
- 6 May 2024
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 34 (4) , 539-555
Estrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions
Estrogen Receptor 1 (ESR1; also known as ERα, encoded byESR1gene) is the main driver and prime drug target in luminal breast cancer. ESR1 chromatin binding is extensively studied in cell lines and a limited number of human tumors, using consensi of peaks shared among samples. However, little is known about inter-tumor heterogeneity of ESR1 chromatin action, along with its biological implications. Here, we use a large set of ESR1 ChIP-seq data from 70 ESR1+breast cancers to explore inter-patient heterogeneity in ESR1 DNA binding to reveal a striking inter-tumor heterogeneity of ESR1 action. Of note, commonly shared ESR1 sites show the highest estrogen-driven enhancer activity and are most engaged in long-range chromatin interactions. In addition, the most commonly shared ESR1-occupied enhancers are enriched for breast cancer risk SNP loci. We experimentally confirm SNVs to impact chromatin binding potential for ESR1 and its pioneer factor FOXA1. Finally, in the TCGA breast cancer cohort, we can confirm these variations to associate with differences in expression for the target gene. Cumulatively, we reveal a natural hierarchy of ESR1–chromatin interactions in breast cancers within a highly heterogeneous inter-tumor ESR1 landscape, with the most common shared regions being most active and affected by germline functional risk SNPs for breast cancer development.
- 6 May 2024
- Published by Cold Spring Harbor Laboratory in Genome Research
- Vol. 34 (4) , 539-555
Open AccessEstrogen receptor 1 chromatin profiling in human breast tumors reveals high inter-patient heterogeneity with enrichment of risk SNPs and enhancer activity at most-conserved regions
Estrogen Receptor 1 (ESR1; also known as ERα, encoded byESR1gene) is the main driver and prime drug target in luminal breast cancer. ESR1 chromatin binding is extensively studied in cell lines and a limited number of human tumors, using consensi of peaks shared among samples. However, little is known about inter-tumor heterogeneity of ESR1 chromatin action, along with its biological implications. Here, we use a large set of ESR1 ChIP-seq data from 70 ESR1+breast cancers to explore inter-patient heterogeneity in ESR1 DNA binding to reveal a striking inter-tumor heterogeneity of ESR1 action. Of note, commonly shared ESR1 sites show the highest estrogen-driven enhancer activity and are most engaged in long-range chromatin interactions. In addition, the most commonly shared ESR1-occupied enhancers are enriched for breast cancer risk SNP loci. We experimentally confirm SNVs to impact chromatin binding potential for ESR1 and its pioneer factor FOXA1. Finally, in the TCGA breast cancer cohort, we can confirm these variations to associate with differences in expression for the target gene. Cumulatively, we reveal a natural hierarchy of ESR1–chromatin interactions in breast cancers within a highly heterogeneous inter-tumor ESR1 landscape, with the most common shared regions being most active and affected by germline functional risk SNPs for breast cancer development.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
The purpose of this study was to identify critical pathways promoting survival of tamoxifen-tolerant, estrogen receptor α positive (ER+) breast cancer cells, which contribute to therapy resistance and disease recurrence. Gene expression profiling and pathway analysis were performed in ER+ breast tumors of patients before and after neoadjuvant tamoxifen treatment and demonstrated activation of the NF-κB pathway and an enrichment of epithelial-to mesenchymal transition (EMT)/stemness features. Exposure of ER+ breast cancer cell lines to tamoxifen, in vitro and in vivo, gives rise to a tamoxifen-tolerant population with similar NF-κB activity and EMT/stemness characteristics. Small-molecule inhibitors and CRISPR/Cas9 knockout were used to assess the role of the NF-κB pathway and demonstrated that survival of tamoxifen-tolerant cells requires NF-κB activity. Moreover, this pathway was essential for tumor recurrence following tamoxifen withdrawal. These findings establish that elevated NF-κB activity is observed in breast cancer cell lines under selective pressure with tamoxifen in vitro and in vivo, as well as in patient tumors treated with neoadjuvant tamoxifen therapy. This pathway is essential for survival and regrowth of tamoxifen-tolerant cells, and, as such, NF-κB inhibition offers a promising approach to prevent recurrence of ER+ tumors following tamoxifen exposure.Implications:Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
The purpose of this study was to identify critical pathways promoting survival of tamoxifen-tolerant, estrogen receptor α positive (ER+) breast cancer cells, which contribute to therapy resistance and disease recurrence. Gene expression profiling and pathway analysis were performed in ER+ breast tumors of patients before and after neoadjuvant tamoxifen treatment and demonstrated activation of the NF-κB pathway and an enrichment of epithelial-to mesenchymal transition (EMT)/stemness features. Exposure of ER+ breast cancer cell lines to tamoxifen, in vitro and in vivo, gives rise to a tamoxifen-tolerant population with similar NF-κB activity and EMT/stemness characteristics. Small-molecule inhibitors and CRISPR/Cas9 knockout were used to assess the role of the NF-κB pathway and demonstrated that survival of tamoxifen-tolerant cells requires NF-κB activity. Moreover, this pathway was essential for tumor recurrence following tamoxifen withdrawal. These findings establish that elevated NF-κB activity is observed in breast cancer cell lines under selective pressure with tamoxifen in vitro and in vivo, as well as in patient tumors treated with neoadjuvant tamoxifen therapy. This pathway is essential for survival and regrowth of tamoxifen-tolerant cells, and, as such, NF-κB inhibition offers a promising approach to prevent recurrence of ER+ tumors following tamoxifen exposure.Implications:Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Data from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
The purpose of this study was to identify critical pathways promoting survival of tamoxifen-tolerant, estrogen receptor α positive (ER+) breast cancer cells, which contribute to therapy resistance and disease recurrence. Gene expression profiling and pathway analysis were performed in ER+ breast tumors of patients before and after neoadjuvant tamoxifen treatment and demonstrated activation of the NF-κB pathway and an enrichment of epithelial-to mesenchymal transition (EMT)/stemness features. Exposure of ER+ breast cancer cell lines to tamoxifen, in vitro and in vivo, gives rise to a tamoxifen-tolerant population with similar NF-κB activity and EMT/stemness characteristics. Small-molecule inhibitors and CRISPR/Cas9 knockout were used to assess the role of the NF-κB pathway and demonstrated that survival of tamoxifen-tolerant cells requires NF-κB activity. Moreover, this pathway was essential for tumor recurrence following tamoxifen withdrawal. These findings establish that elevated NF-κB activity is observed in breast cancer cell lines under selective pressure with tamoxifen in vitro and in vivo, as well as in patient tumors treated with neoadjuvant tamoxifen therapy. This pathway is essential for survival and regrowth of tamoxifen-tolerant cells, and, as such, NF-κB inhibition offers a promising approach to prevent recurrence of ER+ tumors following tamoxifen exposure.Implications:Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
The purpose of this study was to identify critical pathways promoting survival of tamoxifen-tolerant, estrogen receptor α positive (ER+) breast cancer cells, which contribute to therapy resistance and disease recurrence. Gene expression profiling and pathway analysis were performed in ER+ breast tumors of patients before and after neoadjuvant tamoxifen treatment and demonstrated activation of the NF-κB pathway and an enrichment of epithelial-to mesenchymal transition (EMT)/stemness features. Exposure of ER+ breast cancer cell lines to tamoxifen, in vitro and in vivo, gives rise to a tamoxifen-tolerant population with similar NF-κB activity and EMT/stemness characteristics. Small-molecule inhibitors and CRISPR/Cas9 knockout were used to assess the role of the NF-κB pathway and demonstrated that survival of tamoxifen-tolerant cells requires NF-κB activity. Moreover, this pathway was essential for tumor recurrence following tamoxifen withdrawal. These findings establish that elevated NF-κB activity is observed in breast cancer cell lines under selective pressure with tamoxifen in vitro and in vivo, as well as in patient tumors treated with neoadjuvant tamoxifen therapy. This pathway is essential for survival and regrowth of tamoxifen-tolerant cells, and, as such, NF-κB inhibition offers a promising approach to prevent recurrence of ER+ tumors following tamoxifen exposure.Implications:Understanding initial changes that enable survival of tamoxifen-tolerant cells, as mediated by NF-κB pathway, may translate into therapeutic interventions to prevent resistance and relapse, which remain major causes of breast cancer lethality.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figures 1-6 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Figure 1. Tamoxifen treatment induces expression of NFκBB-related genes. Supplementary Figure 2. Immune cell composition and numbers in the tumor microenvironment do not significantly change upon tamoxifen treatment. Supplementary Figure 3. NFκB pathway and EMT/stemness factors in tamoxifen-tolerant persisters in T47D cells. Supplementary Figure 4. Expression of p65 and p50 proteins in MCF-7 CRISPR/Cas9 knock out clones. Supplementary Figure 5. NFκB pathway is not directly activated by tamoxifen. Supplementary Figure 6. Sorted NFκB+ vs NFκBâ^' or unsorted tamoxifen-tolerant cells based on GFP expression were reseeded for another round of clonogenic assay and the %GFP+ population was quantified in the second round.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures 1-6 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Figure 1. Tamoxifen treatment induces expression of NFκBB-related genes. Supplementary Figure 2. Immune cell composition and numbers in the tumor microenvironment do not significantly change upon tamoxifen treatment. Supplementary Figure 3. NFκB pathway and EMT/stemness factors in tamoxifen-tolerant persisters in T47D cells. Supplementary Figure 4. Expression of p65 and p50 proteins in MCF-7 CRISPR/Cas9 knock out clones. Supplementary Figure 5. NFκB pathway is not directly activated by tamoxifen. Supplementary Figure 6. Sorted NFκB+ vs NFκBâ^' or unsorted tamoxifen-tolerant cells based on GFP expression were reseeded for another round of clonogenic assay and the %GFP+ population was quantified in the second round.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Table 1. Patient characteristics.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Table 1. Patient characteristics.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Table 3. GSEA enrichment plots
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Table 3. GSEA enrichment plots
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Materials and Methods and Figure Legends from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Materials and Methods and Figure Legends
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials and Methods and Figure Legends from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Materials and Methods and Figure Legends
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 1 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Table 1. Patient characteristics.
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 1 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Table 1. Patient characteristics.
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Table 3 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Table 3. GSEA enrichment plots
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Table 3 from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Table 3. GSEA enrichment plots
- Open Access
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Supplemental Materials and Methods and Figure Legends from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Materials and Methods and Figure Legends
- 3 April 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Materials and Methods and Figure Legends from The NF-κB Pathway Promotes Tamoxifen Tolerance and Disease Recurrence in Estrogen Receptor–Positive Breast Cancers
Supplemental Materials and Methods and Figure Legends